Table 2 Factors associated with EFS, OS,... | American Society of Hematology

Table 2

Factors associated with EFS, OS, and PFS

Variable	No. of patients	EFS			OS			No. of patients	PFS
Variable	No. of patients	No. of events	6-year EFS rate (%)	P	No. of deaths	6-year OS rate (%)	P	No. of patients	No. of progression	6-year PFS rate (%)	P
Total	132	57	60.6		41	63.0		127	39	63.2
Age, y				.954			.390				.395
< 40	61	25	53.5		19	62.9		59	19	60.9
≥ 40	71	32	47.3		22	59.8		68	20	64.9
Sex				.059			.148				.253
Male	81	40	45.3		28	57.8		77	25	64.4
Female	51	17	55.8		13	69.8		50	14	60.9
CML duration, mo				.000			.001				.000
< 12	61	11	80.0		7	86.9		59	4	92.0
12-36	26	17	32.0		12	49.7		25	12	51.2
> 36	45	29	32.2		22	48.4		43	23	42.5
Disease status at diagnosis of CML				.008			.036				.009
AP	31	6	76.3		4	83.7		47	3	88.4
CP	101	51	44.2		37	58.3		80	36	56.8
Splenomegaly				.658			.610				.284
Yes	48	21	48.9		15	63.1		46	16	61.8
No	84	36	52.9		26	63.3		81	23	64.3
WBC count, × 10⁹/L				.301			.341				.297
< 30	92	42	49.3		31	61.4		88	30	60.4
≥ 30	40	15	51.1		10	63.4		39	9	69.0
Hemoglobin, g/L				.005			.002				.025
< 100	46	25	39.6		20	47.4		42	17	53.8
≥ 100	86	32	56.6		21	70.9		85	22	68.1
Platelet count, × 10⁹/L				.000			.000				.000
< 100	17	12	29.4		10	38.2		14	8	42.9
100-450	51	23	52.0		19	56.1		50	20	55.5
> 450	64	22	53.8		12	72.9		63	11	74.5
PB blasts, %				.002			.004				.004
< 5	118	48	52.4		34	68.7		114	32	65.6
≥ 5	14	9	35.7		7	45.1		13	7	46.2
PB basophils, %				.447			.045				.681
< 5	54	23	56.0		20	60.7		52	15	68.1
≥ 5	78	34	43.3		21	63.4		75	24	58.7
BM blasts, %				.073			.059				.107
< 10	107	43	51.2		31	63.8		105	31	62.0
≥ 10	25	14	42.4		10	55.7		22	8	63.6
AP features				.051			.337				.028
Clonal evolution only	13	3	76.9		3	72.5		12	1	90.0
Hematologic features only	87	37	49.6		27	61.9		85	26	63.3
Both of the above	32	17	36.2		11	40.6		30	12	49.6
Therapy				.008			.023				.000
Imatinib	87	45	39.2		34	51.4		83	37	48.3
Allo-HSCT	45	12	71.8		7	83.3		44	2	95.2

Variable	No. of patients	EFS			OS			No. of patients	PFS
Variable	No. of patients	No. of events	6-year EFS rate (%)	P	No. of deaths	6-year OS rate (%)	P	No. of patients	No. of progression	6-year PFS rate (%)	P
Total	132	57	60.6		41	63.0		127	39	63.2
Age, y				.954			.390				.395
< 40	61	25	53.5		19	62.9		59	19	60.9
≥ 40	71	32	47.3		22	59.8		68	20	64.9
Sex				.059			.148				.253
Male	81	40	45.3		28	57.8		77	25	64.4
Female	51	17	55.8		13	69.8		50	14	60.9
CML duration, mo				.000			.001				.000
< 12	61	11	80.0		7	86.9		59	4	92.0
12-36	26	17	32.0		12	49.7		25	12	51.2
> 36	45	29	32.2		22	48.4		43	23	42.5
Disease status at diagnosis of CML				.008			.036				.009
AP	31	6	76.3		4	83.7		47	3	88.4
CP	101	51	44.2		37	58.3		80	36	56.8
Splenomegaly				.658			.610				.284
Yes	48	21	48.9		15	63.1		46	16	61.8
No	84	36	52.9		26	63.3		81	23	64.3
WBC count, × 10⁹/L				.301			.341				.297
< 30	92	42	49.3		31	61.4		88	30	60.4
≥ 30	40	15	51.1		10	63.4		39	9	69.0
Hemoglobin, g/L				.005			.002				.025
< 100	46	25	39.6		20	47.4		42	17	53.8
≥ 100	86	32	56.6		21	70.9		85	22	68.1
Platelet count, × 10⁹/L				.000			.000				.000
< 100	17	12	29.4		10	38.2		14	8	42.9
100-450	51	23	52.0		19	56.1		50	20	55.5
> 450	64	22	53.8		12	72.9		63	11	74.5
PB blasts, %				.002			.004				.004
< 5	118	48	52.4		34	68.7		114	32	65.6
≥ 5	14	9	35.7		7	45.1		13	7	46.2
PB basophils, %				.447			.045				.681
< 5	54	23	56.0		20	60.7		52	15	68.1
≥ 5	78	34	43.3		21	63.4		75	24	58.7
BM blasts, %				.073			.059				.107
< 10	107	43	51.2		31	63.8		105	31	62.0
≥ 10	25	14	42.4		10	55.7		22	8	63.6
AP features				.051			.337				.028
Clonal evolution only	13	3	76.9		3	72.5		12	1	90.0
Hematologic features only	87	37	49.6		27	61.9		85	26	63.3
Both of the above	32	17	36.2		11	40.6		30	12	49.6
Therapy				.008			.023				.000
Imatinib	87	45	39.2		34	51.4		83	37	48.3
Allo-HSCT	45	12	71.8		7	83.3		44	2	95.2

PB indicates peripheral blood; and BM, bone marrow